

Research and Reviews: Research Journal of Biology

Using Metformin for Cancer Prevention/Treatment

Rachana N*

Department of Biotechnology, Presidency College, Bangalore, India

Review Article

Received: 06/08/2016

Accepted: 22/08/2016

Published: 26/08/2016

*For Correspondence

Rachana N, Department of Biotechnology, Presidency College, Bangalore, India

E-Mail:

Rachana.nandigama162@gmail.com,
rachananandigama@yahoo.com

Keywords: Metformin, Biguanides, AMP-Activated protein kinase (AMPK), Trastuzumab.

ABSTRACT

Metformin belongs to the class *biguanides*. Unlike metformin, phenformin and buformin also belong to biguanides which are developed for type-2 diabetes. These biguanides are derived from the herb *Galega officinalis* (French lilac, also known as Goat's Rue or Italian Fitch). Among these Metformin is used widely and taken orally as it is used as anticancer agent. The trade name of Metformin in the market is Glucophage. Metformin helps to control sugar levels in the blood by decreasing the production of glucose in the liver. It also decreases the amount of glucose that is absorbed from the food and increases body's response to insulin, which naturally controls glucose levels in blood. Hence it can be used in the treatment of cancers which are associated with hyperinsulinemia, such as those of the breast and colon. Metformin was discovered in 1922 and it was introduced in 1950s along with phenformin in to the market. Unlike metformin, the other biguanides (phenformin, buformin) were toxic and often caused fatal condition, hence removed from the U.S. market in 1977. This affected the use of metformin in the market. It is also used to treat people with polycystic ovary syndrome in females but cannot be used to treat people with liver diseases or kidney disorders. It has common side effects like nausea, vomitings, diarrhoea, weakness, breathlessness, abdominal pain. Hence, the U.S. Food and Drug Administration (FDA) required large safety studies of metformin.

The review would cover the topics like How the drug has come into the society? How far the drug was useful to the society and pharmaceutical industries? What advantages and disadvantages the drug has? How it can be used as an anticancer agent? How it improves the survival of some breast cancer patients?

DESCRIPTION

WHAT METFORMIN DOES?

At the cell level, metformin initiates AMP-activated protein kinase (AMPK), a vitality sensor required in directing cell digestion system that is enacted by expansions in the intracellular levels of AMP [1-4]. Metformin by implication enacts AMPK by disturbing complex I of the mitochondrial respiratory chain, which prompts diminished ATP combination and an ascent in the cell AMP: ATP proportion [5-7]. Expanded relationship of AMPK with AMP under such conditions prompts incitement of AMPK action by three components. AMP allosterically enacts AMPK and encourages phosphorylation of its synergist subunit on buildup Thr172 by the upstream kinase liver kinase B1 (LKB1, otherwise called STK11), the protein result of the tumor silencer quality transformed in the Peutz-Jeghers malignancy inclination disorder [8-10]. Official of AMP to AMPK likewise forestalls dephosphorylation of AMPK Thr172 by protein phosphatases. Enacted AMPK phosphorylates various downstream targets prompting incitement of catabolic procedures that produce ATP, for example, unsaturated fat β -oxidation and glycolysis, and concealment of a number of the procedures subject to adequate cell ATP supply, including gluconeogenesis, protein and unsaturated fat amalgamation and cholesterol biosynthesis [11-13].

The system of metformin activity in the treatment of diabetes includes the restraint of hepatic gluconeogenesis and the incitement of glucose uptake in muscle [14,15]. These impacts are accomplished by AMPK-

interceded transcriptional control of qualities required in gluconeogenesis in the liver and those encoding glucose transporters in the muscle, for example, peroxisome proliferator-initiated receptor- γ coactivator 1 α (PGC-1 α) and glucose transporter sort 4 (GLUT4), separately [16,17]. Thus, metformin improves insulin affectability and brings down fasting blood glucose and insulin in diabetics.

METFORMIN IN CANCER PATIENTS

The potential for utilization of metformin in oncology was recognised in epidemiological investigations of diabetic patients with cancer. Through many studies it is observed that tumor rate and its malignancy is decreased with the use of standard doses of metformin [18-23]. For instance, Evans and colleagues reported decreased danger effects with the subsequent use of metformin in diabetic patients with cancer (vs those who do not take metformin), and also defensive impact increases with greater exposure to the drug. Additional studies analysing all types of malignancy have reported decreased disease hazard in diabetics on metformin (vs no metformin treatment) tumor related mortality in patients getting metformin contrasted with those accepting other standard diabetic treatments. Besides, a late epidemiological investigation of 2,529 ladies with breast cancer reported higher pathologic complete reaction rates (pCRs; considered a surrogate for general survival in this setting) to neoadjuvant systemic treatment in diabetic patients accepting metformin (pCR 24%) contrasted with diabetic patients not getting metformin (pCR 8%) and non-diabetic patients not accepting metformin (pCR 16%) [24]. However, inspite of expansion in pCR, metformin did not altogether enhance the evaluated 3-year backslide free survival rate in this study. Moreover, a comparative investigation in diabetics with prostate cancer with the use of drug did not show much benefits [25]. Thus, further clinical exploration is expected for tumor recurrence and survival with the impact of metformin.

While the restrospective studies involving diabetics have shown the major result of use of metformin in cancer treatment. In a recent study, less amount of metformin decreased the number of rectal aberrant crypt foci (a surrogate marker for colorectal cancer) and proliferative activity of colonic epithelium in non-diabetic patients [26]. Moreover, between times investigations of continuous studies including neoadjuvant metformin treatment of breast cancer patients have shown that metformin is safe and tolerated. It also showed good effects on insulin metabolism and malignancy and apoptosis [27-29].

In a cell culture, metformin also shows inhibitory effects on proliferation of mouse tumor models and cancer cells including breast, prostate, colon, endometrial, ovarian, and glioma [30-35]. The impact of metformin on tumor cells were associated with AMPK activation, lessened mammalian focus of rapamycin and protein synthesis, also from other responses including increased expression of p27 [36]. While not generally seen in all cells, drug has been found o induce apoptosis in certain cell lines derived from endometrial cancers, glioma, and triple negative breast tumors [37].

Further studies, showed that the use of metformin also targeted the cancer-initiating cells. For instance, the ability to form tumors in mice was decreased with the use of metformin because of its inhibitory effects on breast cancer cells [38-41]. Metformin when combined with trastuzumab, it decreases the cancer-initiating cells in Her2-amplified breast cancer cells [42,43]. Likewise, it may also control the cancer-initiating cells by transcriptionally repressing the procedure of epithelial to mesenchymal [44-47]. Metformin also supresses the development of breast, colon and other tumors in transgenic mice and decreases tumor xenografts those established form breast and prostate cancer cells [48,49].

MECHANISM OF METFORMIN

The action of the drug can be both direct (insulin- independent) and indirect (insulin-dependent). The impact of metformin in indirect, insulin-dependent action can be noticed by AMPK ability to inhibit transcription of gluconeogenesis genes in liver and stimulate the uptake of glucose by muscles, further decreasing blood glucose and insulin [50-52]. The insulin-lowering impact of metformin plays a major role in its anticancer action since insulin has mitogenic and prosurvival impacts. The cancer cells rarely express high amounts of insulin receptors, indicating potential impacts to the growth promoting hormones [53]. Hence, obesity and high insulin levels are predictable factors for a variety of cancers particularly seen in those with breast, prostate and colon cancers [54-57]. Thus, metformin may reduce the negative impacts of insulin on cancer development. Also it supresses the stimulatory impact of obesity and hyperinsulinemia on lung tumor growth in mice by increasing insulin sensitivity, lowering circulating insulin, and activating AMPK signaling [58]. Likewise, metformin decreased flowing insulin levels by 22% and enhanced insulin affectability by 25% in non-diabetic women with breast cancer, highlighting the insulin-lowering impacts of metformin as a potential system of activity in the treatment of breast cancer [59,60].

The impact of metformin in direct, insulin-independent start from LKB1-mediated activation of AMPK and decrease in mTOR signaling and protein synthesis in cancer cells. AMPK impacts mTOR through phosphorylation and initiation of the tumor silencer tuberous sclerosis complex 2 (TSC2, tuberlin), which negatively regulates mTOR action [61-63]. mTOR is an important mediator of the phosphatidylinositol-3-kinase/protein kinase B/Akt (PI3K/PKB/Akt) signaling pathway, which is a standout amongst the most frequently deregulated molecular networks in human cancer [64,65]. Metformin-mediated AMPK acivation leads to hindrance of mTOR signaling, a

lessening in phosphorylation of its major downstream effectors, the eukaryotic start variable 4E-restricting proteins (4E-BPs) and ribosomal protein S6 kinases (S6Ks), and a restraint of worldwide protein union and expansion in various diverse growth cell lines [66-70].

Few recent studies raise the possibility that metformin may intervene additional anticancer impacts independent of AMPK, LKB1 and TSC2 [71,72]. Which means it inhibits Rag GTPase-mediated activation of mTOR by decreasing the mTOR signalling. Incomprehensibly, at least in one cell model framework, loss of capacity of LKB1 sensitized cells to the inhibitory impacts of metformin under states of low glucose [73-75]. Also, metformin lessened hepatic gluconeogenesis by lowering hepatic energy levels without AMPK and LKB1 [76-80]. While these extra impacts are captivating, LKB1-dependent suppression of mTOR signalling remains the key hopeful instrument of antitumor activity of metformin [81-83].

CONCLUSION

In accordance with the recent convergence of clinical, preclinical and epidemiologic evidences, we can safely assume that it is in race for becoming the best anticancer agent due to its low cost, tested and tried pharmacodynamics profile. But there are still many gaps for this drug to become the silver bullet for cancer among human race. For instance, lack of confirmation for of potential anticancer effects of metformin which were tried only diabetic patients initially. The actions of mechanism of this drug depicted by cell structure and mouse models were artificial and totally relying on non-physiological doses when insulin is in excess in the patient [84,85]. Now to have a better understanding of action of mechanism, more physiological 'in-vitro' models are needed that are more relevant in giving enough reason (in both insulin dependent and independent cases) to the clinical community. Even further, more research is required in figuring out of key patient and tumour factors which define metformin's sensitivity. And this is very much critical in identification of patients which may be best suited to be treated with this drug.

However there are many clinical trials examining the use of metformin as an anticancer agent are underway covering different lines of studies in breast, pancreatic, endometrial and prostate cancer patients. When we have right preclinical models being applied to this data, rest assured metformin could be that one good anticancer drug in the coming years.

REFERENCES

1. Omu AE, et al. Genital Operations and Male Infertility: Is Inguinal Hernia a Component of Testicular Dysgenesis Syndrome?. *J Genit Syst Disor.* 2016;S2.
2. Joffe M. What is Wrong with the Human Reproductive System?. *J Genit Syst Disor.* 2016;S2.
3. Dasgupta M, et al. Is N-acetylcysteine a better Insulin Sensitizer than Metformin in Polycystic Ovarian Syndrome?. *Androl Gynecol: Curr Res.* 2015;3:3.
4. Lauszus FF and Gade M. Hirsutism in PCOS - Low Satisfaction of Treatment and its Background. *J Genit Syst Disor.* 2014;3:3.
5. Lauszus FF, et al. Metformin Exposure in Early Pregnancy and Spontaneous Abortions in Women with Polycystic Ovary Syndrome. *Androl Gynecol: Curr Res.* 2014;2:4.
6. Abdellatif AAH and Tawfeek HM. Metformin Loaded Carbopol Gel for lowering the Intra-Abdominal Visceral Fat. *J Bioequiv Availab.* 2016;8:149-152.
7. Jiang JH, et al. The Changes of the Expression of PGC-1 α and the Level of Oxidative Stress in NAFLD as well as the Effects of Metformin on NAFLD. *J Metabolic Syndr.* 2015;5:193.
8. Bose CK and Basu N. Metformin in Ovarian Cancer. *Oncol Trans Res.* 2015;1:102.
9. Chong RW, et al. Metformin is Beneficial in DM2 Patients with Prostate Cancer. *JPS Open Access.* 2016;1:101.
10. Usta A and Asmatulu R. Synthesis and Analysis of Electrically Sensitive Hydrogels Incorporated with Cancer Drugs. *J Pharm Drug Deliv Res.* 2016;5:2.
11. Guest TC and Rashid S. Anticancer Laccases: A Review. *J Clin Exp Oncol.* 2016;5:1

12. Rhoten BA, et al. Hide and Seek: Body Image-Related Issues for Breast Cancer Survivors with Lymphedema. *J Womens Health, Issues Care*. 2015;4:2.
13. Eljedi A and Nofal M. Health-Related Quality of Life and its Influencing Factors among Breast Cancer Patients in Palestine. *J Womens Health, Issues Care*. 2014;3:5.
14. Madsen MT, et al. Actigraphy can be used to Quantify Sleep in the Perioperative Period in Women Undergoing Breast Cancer Surgery: A Validation Study. *J Sleep Disor: Treat Care*. 2014;3:4.
15. Suleyman N, et al. Classification, Epidemiology and Therapies for Testicular Germ Cell Tumours. *J Genit Syst Disor*. 2016;S2.
16. Santos EMS, et al. Obesity-Related Genes and Oral Cancer: A Bioinformatics Approach and Systematic Review. *J Appl Bioinform Comput Biol*. 2016;5:1.
17. Kumar R, et al. Quantum Magnetic Resonance Therapy: Targeting Biophysical Cancer Vulnerabilities to Effectively Treat and Palliate. *J Clin Exp Oncol*. 2016;5:2.
18. Norollahi SE, et al. The Role of MicroRNAs in Cancer Progression. *J Clin Exp Oncol*. 2016;5:2.
19. Araújo DV, et al. Evaluation of Sleep Quality in Patients with Breast Cancer. *J Sleep Disor: Treat Care*. 2014;3:4.
20. Lima FPA. Artificial Immune Systems with Negative Selection Applied To Clinical Diagnosis of Breast Cancer Samples. *J Comput Eng Inf Technol*. 2014;3:1.
21. Almukainzi M, et al. Modelling the Absorption of Metformin with Patients Post Gastric Bypass Surgery. *J Diabetes Metab*. 2014;5:353.
22. Friedrich C, et al. Bioequivalence of Glucophage® (Metformin) Tablets from Europe and the United States Tested in Healthy Volunteers. *J Bioequiv Availab*. 2014;6:061-066.
23. Oliveira AG and Gomes-Marcondes MCC. Metformin Improves Carbohydrate Metabolism and Minimizes Walker Tumor Growth in Young Rats. *Biochem Pharmacol*. 2014;3:125.
24. Oleksyszyn J, et al. Cancer – Could it be Cured? A Spontaneous Regression of Cancer, Cancer Energy Metabolism, Hyperglycemia-Hypoglycemia, Metformin, Warburg and Crabtree Effects and a New Perspective in Cancer Treatment. *J Cancer Sci Ther*. 2014;6:056-061.
25. Sultana N, et al. An Ultra-Sensitive and Selective LC-UV Method for the Simultaneous Determination of Metformin, Pioglitazone, Glibenclamide and Glimepride in API, Pharmaceutical Formulations and Human Serum. *J Anal Bioanal Tech*. 2013;5:176.
26. Naveed S, et al. Degradation Study of Available Brands of Metformin in Karachi Using UV Spectrophotometer. *J Diabetes Metab*. 2014;5:328.
27. Wedrychowicz A, et al. Effectiveness of Metformin Treatment in the Teenager with Maturity-Onset Diabetes of the Young Type 3 and Oligomenorrhoea: A Case Presentation. *J Diabetes Metab*. 2014;5:327.
28. Cadeddu C, et al. Effects of Metformin Treatment on Myocardial and Endothelial Function in Insulin Resistance Patients: A Metabolomic Study. *J Diabetes Metab*. 2013;4:279.
29. Sultana N, et al. Development and Validation of a Simple and Efficient RPLC Method for Analysis of Captopril, Metformin, Pioglitazone and Glibenclamide in API, Formulations and Human Serum. *Pharm Anal Acta*. 2013;4:257.
30. Paintlia AS, et al. Combinatorial Effect of Metformin and Lovastatin Impedes T-cell Autoimmunity and Neurodegeneration in Experimental Autoimmune Encephalomyelitis. *J Clin Cell Immunol*. 2013;4:149.

31. Ginter AC and Braun B. 'Female Breast Cancer Patients' Need for Social Support: Implications for Patients without Partners and Health Care Professionals. *J Womens Health, Issues Care*. 2014;3:3.
32. Atalay C, et al. Impact of Loco-Regional Under-treatment in Elderly Patients with Early Breast Cancer (Protocol Yameka-09sdl); Multi-Centric Retrospective Cohort Study. *J Clin Exp Oncol*. 2014;3:1.
33. Savitri SC and Cindy G. Breast Cancer Survivorship – Optimizing Follow-up Care: Patients' Perspectives of their Practical Needs. *J Womens Health, Issues Care*. 2014;3:1.
34. Alipour S and Eskandari. A Perspectives of Maternity after Breast Cancer. *Androl Gynecol: Curr Res*. 2013;2:1.
35. Merten JW, et al. Rural Breast Cancer Patients and Survivor's Perspectives using Online Health Resources. *J Womens Health, Issues Care*. 2013;2:6.
36. Tengli AR, et al. Method Development and Validation of Metformine, Pioglitazone and Glibenclamide in Tablet Dosage Form by using RP-HPLC. *Biochem Anal Biochem*. 2013;2:130.
37. Bradford SA and Khan A. Individualizing Chemotherapy using the Anti-Diabetic Drug, Metformin, as an "Adjuvant": An Exploratory Study. *J Cancer Sci Ther*. 2013;5:120-125.
38. Bhaskar R, et al. UV Spectrophotometric- Assisted Chemometric Methods for the Simultaneous Determination of Metformin Hydrochloride and Gliclazide in Pharmaceutical Formulations. *Pharmaceut Anal Acta*. 2012;3:158.
39. Dong M, et al. The Effect of PTPRd rs17584499 C/T Polymorphism on Therapeutic Efficacy of Metformin in Chinese Patients with Type 2 diabetes. *J Diabetes Metab*. 2012;3:186.
40. Kumar NB, et al. Metformin- A Promising Agent for Chemoprevention in BRCA1 Carriers. *Hereditary Genetics*. 2012;1:104.
41. Bashmakov YK and Petyaev IM. Old Drug Acquires New Target: Metformin and SIRT1. *J Diabetes Metab*. 2011;2:107e.
42. Idkaidek N, et al. Metformin IR versus XR Pharmacokinetics in Humans. *J Bioequiv Availab*. 2011;3: 233-235.
43. Abbas M, et al. Bioequivalence Evaluation of a Combine Formulation of Pioglitazone/Metformin in Healthy Pakistani Volunteers. *J Bioequiv Availab*. 2011;3:092-096.
44. Havele S and Dhaneshwar S. Estimation of Metformin in Bulk Drug and in Formulation by HPTLC. *J Nanomedic Nanotechnolo*. 2010;1:102.
45. Harahap Y, et al. Bioequivalence Study of Metformin HCl XR Caplet Formulations in Healthy Indonesian Volunteers. *J Bioequiv Availab*. 2011;3:016-019.
46. Dhaneshwar SR, et al. Validated HPTLC Method for Simultaneous Estimation of Metformin Hydrochloride, Atorvastatin and Glimepiride in Bulk Drug and Formulation. *J Anal Bioanal Tech*. 2010;1:109.
47. Rao BU and Nikalje AP. Determination of Glipizide, Glibenclamide and Glimeperide in a Tablet Dosage Form in the Presence of Metformin Hydrochloride by Ion Pair –Reversed Phase Liquid Chromatographic Technique. *J Anal Bioanal Tech*. 2010;1:105.
48. Mahapatra S, et al. Glomus Tumor in Vulva with Uncertain Malignant Potential. *J Womens Health, Issues Care*. 2013;2:5.
49. Abolfotouh MA, et al. Case-control Study of Breast Cancer and Dietary Fat Intake in Saudi Females. *J Womens Health, Issues Care*. 2013;2:5.

50. Shah C, et al. Breast Cancer Related Lymphedema: A Review of Recent Developments. *Androl Gynecol: Curr Res.* 2013;1:2.
51. Ngai SC. Epigenetics Interplay between DNA Methylation and Histone Modifications in Breast Cancer. *Adv Genet Eng Biotechnol.* 2012;1:1.
52. Sköld MK, et al. Spinal Intradural Extramedullary Prostate Cancer Metastasis - Report of Two Patients and Review of the Literature. *J Spine Neurosurg.* 2016;5:3.
53. Slaoui W, et al. Unusual Ulcerated Nodules of Scalp with Histological Proof of Cutaneous Metastasis Derived from Prostate Cancer: Report of a Case *J Clin Exp Oncol.* 2015;4:3.
54. Higashino M, et al. Outcome of Tracheostomy Closure in Oral Cancer Surgery Patients. *J Otol Rhinol.* 2016;5:3.
55. Zheng H, et al. Silver Sulfide Nanoparticles as Photothermal Transducing Agents for Cancer Treatment. *J Nanomater Mol Nanotechnol.* 2016;5:2.
56. Usta A and Asmatulu R. Synthesis and Analysis of Electrically Sensitive Hydrogels Incorporated with Cancer Drugs. *J Pharm Drug Deliv Res.* 2016;5:2.
57. Mendes F, et al. Radiotherapy Effects on Immune System of Patients with Solid and Hematopoietic Tumors. *Cell Biol: Res Ther.* 2016;5:1.
58. Oleksyszyn J. Spontaneous Regression of Cancer, an Ever Actual Inspiration for the New Cancer Treatment. *Cell Biol: Res Ther.* 2016;5:1.
59. Sköld MK, et al. Spinal Intradural Extramedullary Prostate Cancer Metastasis - Report of Two Patients and Review of the Literature. *J Spine Neurosurg.* 2016;5:3.
60. Cheng BYL, et al. Revisiting the Role of TLR/IRAK Signaling and its Therapeutic Potential in Cancer. *J Liver: Dis Transplant.* 2015;5:1
61. Guest TC and Rashid S. Anticancer Laccases: A Review. *J Clin Exp Oncol.* 2016;5:1.
62. El-Lathy HA, et al. The Impact of Pretreatment 18F-FDG (PET/CT) Maximum Standardized Uptake Value and Neutrophil/Lymphocyte Ratio (NLR) in Predicting Prognosis in Surgically Treated Oligometastatic Breast Cancer Patients. *J Nucl Med Radiat Ther.* 2015;7:271.
63. Wang HH, et al. Long-Term Survivors of Breast Cancer: Religious Influence. *J Nurs Care.* 2016;5:324.
64. Kabel AM, et al. Ameliorative Potential of Tamoxifen/Thymoquinone Combination in Patients with Breast Cancer: A Biochemical and Immunohistochemical Study. *Cancer Med Anticancer Drug.* 2016;1:102.
65. Jehn CF, et al. Impaired Thinking in Patients with Breast Cancer and Depression. *J Palliat Care Med.* 2016;6:248.
66. Kim JJ, et al. Chemotherapy Increases Aggressiveness of Prostate Cancer via Epithelial Mesenchymal Transition. *Cell Biol: Res Ther.* 2013;2:2.
67. Sheykholeslami K, et al. Asymptomatic Neck Mass as the Only Presenting Symptom of Advanced Prostate Cancer, a Case Report and Literature Review. *J Otol Rhinol.* 2013;2:2.
68. Suy S, et al. Expression of Voltage-Gated Sodium Channel Nav1.8 in Human Prostate Cancer is Associated with High Histological Grade. *J Clin Exp Oncol.* 2012;1:2.
69. Iwao T, et al. Liraglutide With or Without Metformin Ameliorates Liver Function and Fatty Liver in Obese Patients with Type 2 Diabetes Mellitus. *J Diabetes Metab.* 2015;6:598.
70. Tuna MM, et al. Gestational Severe, Nonfamilial Hypertriglyceridemia, Management with Insulin and Metformin, A Case Report. *J Diabetes Metab.* 2014;5:466.

71. Kamenova P, et al. Metformin Reduces Cardiometabolic Risk Factors in People at High Risk for Development of Type 2 Diabetes and Cardiovascular Disease. *J Diabetes Metab.* 2014;5:470.
72. Alkhalaf F, et al. Metformin Use in Adolescents: Old and New Therapeutic Perspectives. *J Diabetes Metab.* 2014;5:472.
73. Barrett HL, et al. Predictors of Preeclampsia in Women in the Metformin in Gestational Diabetes (Mig) Study. *J Diabetes Metab.* 2014;5:395.
74. Dhillon SS, et al. Metformin and Not Diabetes Influences the Survival of Resected Early Stage NSCLC Patients. *J Cancer Sci Ther.* 2014;6:217-222.
75. Patel TN, et al. Telomeres in Cancer: Length, Positioning and Epigenetics. *J Genet Disor Genet Rep.* 2016;5:1.
76. Lokesh BVS and Kumar PV. Enhanced Cytotoxic Effect of Chemically Conjugated Polymeric Sirolimus against HT-29 Colon Cancer and A-549 Lung Cancer Cell Lines. *J Pharm Drug Deliv Res.* 2015;4:2.
77. Tal G and Linda S. Implantable Port-a-Cath System Insertion in Patients with Metastatic Colon Cancer Receiving Bevacizumab-Based Chemotherapy. *Prensa Med Argent.* 2015;101:1.
78. Del Follo-Martinez A, et al. Polyphenolics from Black Spanish Red Wine (*Vitis 'aestivalis'*) have Cytotoxic Activity in Colon Cancer Cells and Repress Pro-oncogenic microRNA-27a. *J Food Nutr Disor.* 2015;4:2.
79. De LeBlanc. The Administration of Probiotics and Fermented Products Containing Lactic Acid Bacteria Exert Beneficial Effects Against Intestinal and Non-Intestinal Cancers. *J Food Nutr Disor.* 2014;S1-005.
80. Garcia SB, et al. Neuropeptides in the Development of Colon Cancer. *Can Surg.* 2016;1:104.
81. Van Pelt GW, et al. Stroma-High Lymph Node Involvement Predicts Poor Survival More Accurately for Patients with Stage III Colon Cancer. 2016.
82. Rosa LS, et al. Anticancer Properties of Phenolic Acids in Colon Cancer – A Review. *J Nutr Food Sci.* 2016;6:468.
83. Turner J, et al. Sigmoid Perforation during CT Colonography in a Patient with an Inguinal Hernia and Concomitant Finding of a Right-Sided Colon Cancer. *J Gastrointest Dig Syst.* 2016;6:378.
84. Dabak TK, et al. Diagnosis of Osteoporosis and Radiotherapy Induced Fracture by F-18 FDG PET/CT in A Case with Colon Cancer. 2016.
85. Naeini EE, et al. The Effectiveness of Stress Management Training on Hardiness in Patients with Breast Cancer. *Abnorm Behav Psychol.* 2016;2:115.